- Published on
Infectious disease and microbiology – Odontogenic infections
Odontogenic infections are infections originating from the teeth or their supporting structures, ranging from minor localized lesions (e.g., dental caries, pulpitis, periapical abscess) to severe deep tissue infections that can spread into the neck and surrounding fascial spaces. These infections are among the most common reasons for dental consultations worldwide, with conditions such as periapical abscesses, periodontal abscesses, and pericoronitis being frequent emergency presentations.
They arise from disruption of the normal oral biofilm, a complex bacterial ecosystem on tooth surfaces. Poor oral hygiene or systemic conditions can alter this balance, allowing pathogenic organisms to proliferate. The infections are typically polymicrobial, involving a mix of aerobic and anaerobic bacteria, most commonly Streptococcus species, anaerobes like Fusobacterium, Peptostreptococcus, and Actinomyces, and others. As disease progresses, there is often a shift from Gram-positive organisms in early gingivitis to Gram-negative anaerobes in advanced periodontitis.
Risk factors include poor oral hygiene, diabetes, immunodeficiency, malnutrition, smoking, pregnancy, advanced age, and reduced salivation. Hospitalized patients may have increased colonization with Gram-negative organisms, increasing the risk of more severe infections. Preventive strategies focus on maintaining oral hygiene, fluoride use, plaque control (e.g., chlorhexidine), and regular dental care.
Clinically, presentation varies by the specific condition. Pulpitis and periapical abscesses typically begin with tooth sensitivity to hot or cold, progressing to persistent, throbbing pain. Gingivitis presents with inflamed, bleeding gums and halitosis, while periodontitis leads to tooth mobility, pain, and pus formation due to destruction of supporting tissues. Severe infections may extend into deep fascial spaces, causing swelling, fever, trismus, dysphagia, and systemic illness.
Diagnosis is primarily clinical, supported by dental imaging such as X-rays, which can identify bone loss, abscesses, and structural damage. Advanced imaging (CT or MRI) is used when infection spreads beyond the oral cavity. Microbiological testing may help guide therapy, although infections are usually polymicrobial.
Management aims to eliminate the source of infection and reduce bacterial load. This typically involves mechanical debridement, drainage of abscesses, and removal of the affected tooth if necessary. Antibiotics are reserved for systemic involvement or severe local spread, with common choices including penicillin, clindamycin, amoxicillin-clavulanate, or combinations such as ampicillin with metronidazole. Regular dental follow-up and periodontal care are essential to prevent recurrence.
Complications can be serious if untreated, including osteomyelitis of the jaw, necrotizing fasciitis, sinusitis, orbital infections, and intracranial spread. A particularly dangerous condition is Ludwig’s angina, a rapidly progressing bilateral infection of the floor of the mouth that can compromise the airway. Other rare but severe complications include cavernous sinus thrombosis, brain abscess, and Lemierre’s syndrome, underscoring the importance of early recognition and treatment.
Odontogenic infections are infections originating from the teeth or their supporting structures, ranging from minor localized lesions (e.g., dental caries, pulpitis, periapical abscess) to severe deep tissue infections that can spread into the neck and surrounding fascial spaces. These infections are among the most common reasons for dental consultations worldwide, with conditions such as periapical abscesses, periodontal abscesses, and pericoronitis being frequent emergency presentations.
They arise from disruption of the normal oral biofilm, a complex bacterial ecosystem on tooth surfaces. Poor oral hygiene or systemic conditions can alter this balance, allowing pathogenic organisms to proliferate. The infections are typically polymicrobial, involving a mix of aerobic and anaerobic bacteria, most commonly Streptococcus species, anaerobes like Fusobacterium, Peptostreptococcus, and Actinomyces, and others. As disease progresses, there is often a shift from Gram-positive organisms in early gingivitis to Gram-negative anaerobes in advanced periodontitis.
Risk factors include poor oral hygiene, diabetes, immunodeficiency, malnutrition, smoking, pregnancy, advanced age, and reduced salivation. Hospitalized patients may have increased colonization with Gram-negative organisms, increasing the risk of more severe infections. Preventive strategies focus on maintaining oral hygiene, fluoride use, plaque control (e.g., chlorhexidine), and regular dental care.
Clinically, presentation varies by the specific condition. Pulpitis and periapical abscesses typically begin with tooth sensitivity to hot or cold, progressing to persistent, throbbing pain. Gingivitis presents with inflamed, bleeding gums and halitosis, while periodontitis leads to tooth mobility, pain, and pus formation due to destruction of supporting tissues. Severe infections may extend into deep fascial spaces, causing swelling, fever, trismus, dysphagia, and systemic illness.
Diagnosis is primarily clinical, supported by dental imaging such as X-rays, which can identify bone loss, abscesses, and structural damage. Advanced imaging (CT or MRI) is used when infection spreads beyond the oral cavity. Microbiological testing may help guide therapy, although infections are usually polymicrobial.
Management aims to eliminate the source of infection and reduce bacterial load. This typically involves mechanical debridement, drainage of abscesses, and removal of the affected tooth if necessary. Antibiotics are reserved for systemic involvement or severe local spread, with common choices including penicillin, clindamycin, amoxicillin-clavulanate, or combinations such as ampicillin with metronidazole. Regular dental follow-up and periodontal care are essential to prevent recurrence.
Complications can be serious if untreated, including osteomyelitis of the jaw, necrotizing fasciitis, sinusitis, orbital infections, and intracranial spread. A particularly dangerous condition is Ludwig’s angina, a rapidly progressing bilateral infection of the floor of the mouth that can compromise the airway. Other rare but severe complications include cavernous sinus thrombosis, brain abscess, and Lemierre’s syndrome, underscoring the importance of early recognition and treatment.
- Published on
Infectious disease and microbiology – Pericarditis
Pericarditis is an inflammatory condition of the pericardium, the sac surrounding the heart, and can result from a wide range of infectious (viral, bacterial, fungal, protozoal) and noninfectious causes. In many cases, especially when no specific pathogen is identified, it is presumed to be viral or idiopathic, often involving an immune-mediated mechanism.
The condition is relatively common in clinical practice, accounting for about 5% of emergency visits for chest pain, though it occurs in only about 0.1% of hospitalized patients. Bacterial pericarditis is much rarer but more severe. There is no specific prevention for idiopathic cases, but early diagnosis and treatment can reduce complications and the need for surgical intervention.
Pathophysiologically, pericarditis may result from direct infection of the pericardium, as seen in bacterial cases, or from an autoimmune response, particularly in idiopathic or viral forms. Tuberculous pericarditis involves immune activation with CD4 lymphocytes and interferon-gamma, while viral infections lead to lymphocytic inflammation of the pericardium.
A wide variety of pathogens can cause pericarditis. Viruses are the most common, especially Coxsackie A and B, along with herpes viruses, influenza, adenovirus, HIV, and others. Bacterial causes often arise from nearby infections like pneumonia or from postoperative or hospital-acquired infections, with organisms such as Staphylococcus aureus, Streptococcus pneumoniae, and gram-negative bacteria. Less commonly, fungi (e.g., Candida, Histoplasma) and protozoa (e.g., Toxoplasma, Entamoeba histolytica) are involved, typically in disseminated disease.
Clinically, patients usually present with sharp, retrosternal chest pain and fever, with pain often relieved by sitting forward, which is a classic feature. Viral prodromal symptoms may be present. In bacterial cases, chest pain may be less prominent. Other findings include tachypnea and tachycardia, and in severe cases, progression to cardiac tamponade. On examination, a pericardial friction rub is characteristic, and signs such as pulsus paradoxus and decreased heart sounds may indicate significant effusion.
Diagnosis relies heavily on electrocardiography (ECG), which typically shows diffuse ST-segment elevation and PR depression, making it one of the most important diagnostic tools. Laboratory findings may include elevated white blood cells and inflammatory markers, and sometimes elevated cardiac troponins. Imaging such as chest X-ray, CT, MRI, or echocardiography helps assess pericardial effusion and structural involvement. Pericardiocentesis or biopsy may be necessary for diagnosis and to relieve tamponade, with fluid analysis aiding in identifying the cause.
Management depends on the underlying etiology. Most cases are treated with nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or indomethacin, along with colchicine, which reduces symptoms and recurrence. Steroids are generally avoided except in specific situations like tuberculous pericarditis. If a specific pathogen is identified, targeted therapy is required—for example, antivirals (e.g., acyclovir, ganciclovir), antibiotics for bacterial causes, or antituberculous therapy. Supportive measures include bed rest and gastric protection when using NSAIDs.
Severe complications such as cardiac tamponade require urgent intervention with pericardiocentesis, while purulent or constrictive pericarditis may necessitate surgical procedures like pericardiotomy or pericardiectomy. Hospitalization is indicated in high-risk patients, including those with fever, large effusions, immunosuppression, or failure of initial therapy.
The prognosis is generally excellent in idiopathic or viral pericarditis, with recovery in most patients. However, outcomes are worse in tuberculous or untreated bacterial pericarditis, which can be fatal. Important complications include recurrence, constrictive pericarditis, and cardiac tamponade, all of which require careful monitoring and follow-up, often with repeat echocardiography.
Pericarditis is an inflammatory condition of the pericardium, the sac surrounding the heart, and can result from a wide range of infectious (viral, bacterial, fungal, protozoal) and noninfectious causes. In many cases, especially when no specific pathogen is identified, it is presumed to be viral or idiopathic, often involving an immune-mediated mechanism.
The condition is relatively common in clinical practice, accounting for about 5% of emergency visits for chest pain, though it occurs in only about 0.1% of hospitalized patients. Bacterial pericarditis is much rarer but more severe. There is no specific prevention for idiopathic cases, but early diagnosis and treatment can reduce complications and the need for surgical intervention.
Pathophysiologically, pericarditis may result from direct infection of the pericardium, as seen in bacterial cases, or from an autoimmune response, particularly in idiopathic or viral forms. Tuberculous pericarditis involves immune activation with CD4 lymphocytes and interferon-gamma, while viral infections lead to lymphocytic inflammation of the pericardium.
A wide variety of pathogens can cause pericarditis. Viruses are the most common, especially Coxsackie A and B, along with herpes viruses, influenza, adenovirus, HIV, and others. Bacterial causes often arise from nearby infections like pneumonia or from postoperative or hospital-acquired infections, with organisms such as Staphylococcus aureus, Streptococcus pneumoniae, and gram-negative bacteria. Less commonly, fungi (e.g., Candida, Histoplasma) and protozoa (e.g., Toxoplasma, Entamoeba histolytica) are involved, typically in disseminated disease.
Clinically, patients usually present with sharp, retrosternal chest pain and fever, with pain often relieved by sitting forward, which is a classic feature. Viral prodromal symptoms may be present. In bacterial cases, chest pain may be less prominent. Other findings include tachypnea and tachycardia, and in severe cases, progression to cardiac tamponade. On examination, a pericardial friction rub is characteristic, and signs such as pulsus paradoxus and decreased heart sounds may indicate significant effusion.
Diagnosis relies heavily on electrocardiography (ECG), which typically shows diffuse ST-segment elevation and PR depression, making it one of the most important diagnostic tools. Laboratory findings may include elevated white blood cells and inflammatory markers, and sometimes elevated cardiac troponins. Imaging such as chest X-ray, CT, MRI, or echocardiography helps assess pericardial effusion and structural involvement. Pericardiocentesis or biopsy may be necessary for diagnosis and to relieve tamponade, with fluid analysis aiding in identifying the cause.
Management depends on the underlying etiology. Most cases are treated with nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or indomethacin, along with colchicine, which reduces symptoms and recurrence. Steroids are generally avoided except in specific situations like tuberculous pericarditis. If a specific pathogen is identified, targeted therapy is required—for example, antivirals (e.g., acyclovir, ganciclovir), antibiotics for bacterial causes, or antituberculous therapy. Supportive measures include bed rest and gastric protection when using NSAIDs.
Severe complications such as cardiac tamponade require urgent intervention with pericardiocentesis, while purulent or constrictive pericarditis may necessitate surgical procedures like pericardiotomy or pericardiectomy. Hospitalization is indicated in high-risk patients, including those with fever, large effusions, immunosuppression, or failure of initial therapy.
The prognosis is generally excellent in idiopathic or viral pericarditis, with recovery in most patients. However, outcomes are worse in tuberculous or untreated bacterial pericarditis, which can be fatal. Important complications include recurrence, constrictive pericarditis, and cardiac tamponade, all of which require careful monitoring and follow-up, often with repeat echocardiography.
- Published on
Infectious disease and microbiology – Parvovirus infection
Parvovirus B19 infection is a common viral illness with a wide spectrum of clinical manifestations, ranging from mild childhood disease to severe complications in high-risk groups. It is best known for causing erythema infectiosum (fifth disease), but it can also lead to transient aplastic crisis in patients with chronic hemolytic anemia, chronic anemia in immunocompromised individuals, and serious fetal complications such as hydrops fetalis and fetal death. Notably, it is responsible for the majority of aplastic crises in conditions like sickle cell disease.
The virus has a global distribution, with humans as the only reservoir. Seroprevalence increases with age, reaching 30–60% in adults, and infection commonly occurs in childhood outbreaks, particularly in late winter and early spring. Transmission occurs mainly via respiratory secretions, but can also occur through blood products, vertical (mother-to-fetus) transmission, and rarely nosocomial exposure.
After an incubation period of about one week, viremia develops and is followed by infection of erythroid precursor cells in the bone marrow, leading to temporary suppression of red blood cell production (pure red-cell aplasia). The characteristic rash and joint symptoms appear later and are immune-mediated. In immunocompromised patients, failure to mount an antibody response may result in persistent infection and chronic anemia.
Clinically, infection often begins with mild flu-like symptoms such as fever, malaise, headache, and myalgias. This is followed by the classic “slapped cheek” facial rash, which may spread as a lacy, reticular rash over the extremities. Joint symptoms, particularly symmetric polyarthropathy affecting the hands, wrists, and knees, are more common in adults, especially women. In patients with hemolytic disorders, the presentation may be dominated by severe anemia, often without rash.
Diagnosis in typical childhood cases is clinical, but laboratory confirmation can be achieved through detection of parvovirus-specific IgM antibodies or a rise in IgG titers. In immunocompromised patients, PCR detection of viral DNA is more reliable, as antibody responses may be absent. In aplastic crises, laboratory findings include severe anemia with low reticulocyte count and characteristic bone marrow findings (giant pronormoblasts).
Management is largely supportive, as infection in immunocompetent individuals is usually self-limited. Nonsteroidal anti-inflammatory drugs may help relieve joint symptoms. In severe cases, such as aplastic crisis or chronic anemia, treatment includes blood transfusions and intravenous immunoglobulin (IVIG). In immunocompromised patients, reducing immunosuppression when possible may aid recovery.
Special consideration is required during pregnancy, as fetal infection can result in severe anemia, hydrops fetalis, and fetal death, particularly in the first half of pregnancy. Monitoring with ultrasound and laboratory testing is essential, and intrauterine transfusion may be needed in severe cases.
The prognosis is excellent in healthy individuals, with most cases resolving without complications. However, complications can occur in vulnerable populations and include severe anemia, chronic infection, fetal loss, hepatitis, myocarditis, meningoencephalitis, and hemophagocytic syndrome. Overall, parvovirus B19 infection highlights the contrast between a typically mild childhood illness and its potentially serious impact in high-risk groups.
Parvovirus B19 infection is a common viral illness with a wide spectrum of clinical manifestations, ranging from mild childhood disease to severe complications in high-risk groups. It is best known for causing erythema infectiosum (fifth disease), but it can also lead to transient aplastic crisis in patients with chronic hemolytic anemia, chronic anemia in immunocompromised individuals, and serious fetal complications such as hydrops fetalis and fetal death. Notably, it is responsible for the majority of aplastic crises in conditions like sickle cell disease.
The virus has a global distribution, with humans as the only reservoir. Seroprevalence increases with age, reaching 30–60% in adults, and infection commonly occurs in childhood outbreaks, particularly in late winter and early spring. Transmission occurs mainly via respiratory secretions, but can also occur through blood products, vertical (mother-to-fetus) transmission, and rarely nosocomial exposure.
After an incubation period of about one week, viremia develops and is followed by infection of erythroid precursor cells in the bone marrow, leading to temporary suppression of red blood cell production (pure red-cell aplasia). The characteristic rash and joint symptoms appear later and are immune-mediated. In immunocompromised patients, failure to mount an antibody response may result in persistent infection and chronic anemia.
Clinically, infection often begins with mild flu-like symptoms such as fever, malaise, headache, and myalgias. This is followed by the classic “slapped cheek” facial rash, which may spread as a lacy, reticular rash over the extremities. Joint symptoms, particularly symmetric polyarthropathy affecting the hands, wrists, and knees, are more common in adults, especially women. In patients with hemolytic disorders, the presentation may be dominated by severe anemia, often without rash.
Diagnosis in typical childhood cases is clinical, but laboratory confirmation can be achieved through detection of parvovirus-specific IgM antibodies or a rise in IgG titers. In immunocompromised patients, PCR detection of viral DNA is more reliable, as antibody responses may be absent. In aplastic crises, laboratory findings include severe anemia with low reticulocyte count and characteristic bone marrow findings (giant pronormoblasts).
Management is largely supportive, as infection in immunocompetent individuals is usually self-limited. Nonsteroidal anti-inflammatory drugs may help relieve joint symptoms. In severe cases, such as aplastic crisis or chronic anemia, treatment includes blood transfusions and intravenous immunoglobulin (IVIG). In immunocompromised patients, reducing immunosuppression when possible may aid recovery.
Special consideration is required during pregnancy, as fetal infection can result in severe anemia, hydrops fetalis, and fetal death, particularly in the first half of pregnancy. Monitoring with ultrasound and laboratory testing is essential, and intrauterine transfusion may be needed in severe cases.
The prognosis is excellent in healthy individuals, with most cases resolving without complications. However, complications can occur in vulnerable populations and include severe anemia, chronic infection, fetal loss, hepatitis, myocarditis, meningoencephalitis, and hemophagocytic syndrome. Overall, parvovirus B19 infection highlights the contrast between a typically mild childhood illness and its potentially serious impact in high-risk groups.
- Published on
Infectious disease and microbiology – Otitis media
Otitis media refers to inflammation of the middle ear, involving the mucosa and periosteum, and encompasses several clinical forms including acute otitis media (AOM), recurrent AOM, otitis media with effusion (OME), and chronic suppurative otitis media (CSOM). Acute otitis media is defined by the presence of middle-ear fluid along with signs of acute infection, whereas OME involves persistent fluid without active infection, and CSOM is characterized by chronic ear discharge through a perforated tympanic membrane, sometimes associated with cholesteatoma.
This condition is extremely common in children, with more than two-thirds experiencing at least one episode before age 3, and a peak incidence between 6–24 months. It is far less common in adults. Risk factors include eustachian tube dysfunction (often following viral upper respiratory infections), daycare attendance, passive smoking, congenital anomalies (e.g., cleft palate), immunodeficiency, and early age of first infection. Preventive strategies emphasize vaccination (pneumococcal, Haemophilus influenzae, influenza), breastfeeding, and appropriate early treatment.
The pathophysiology centers on eustachian tube dysfunction, leading to fluid accumulation in the middle ear, which serves as a medium for microbial growth. Viral infections often precede bacterial infection by causing mucosal swelling and obstruction.
The etiology varies by age and clinical form. In children, the most common pathogens are Streptococcus pneumoniae, Haemophilus influenzae (mostly nontypable), and Moraxella catarrhalis. Other organisms include group A streptococci and Staphylococcus aureus. In neonates, group B streptococci and gram-negative bacilli are important, while in adults, H. influenzae and S. pneumoniae predominate. Chronic suppurative otitis media often involves Pseudomonas aeruginosa, S. aureus, enteric gram-negative bacilli, and anaerobes.
Clinically, acute otitis media presents with ear pain, fever, and hearing loss, while infants may show nonspecific symptoms such as irritability or feeding difficulties. OME is often asymptomatic but may cause a feeling of fullness or mild hearing loss, whereas CSOM presents with chronic purulent discharge and hearing impairment.
Diagnosis relies on otoscopic examination, which typically shows a bulging, erythematous, and immobile tympanic membrane in acute disease, while OME shows a dull, hypomobile membrane without bulging. Tympanometry and hearing tests can help confirm middle-ear fluid and assess hearing loss. In complicated or chronic cases, CT imaging may be required to evaluate for cholesteatoma or mastoid involvement.
Treatment depends on the clinical scenario. Amoxicillin remains the first-line therapy for most cases of acute otitis media, with alternatives such as amoxicillin-clavulanate or cephalosporins used in resistant or recurrent cases. Macrolides or TMP-SMX may be used in penicillin-allergic patients. A watchful waiting approach may be appropriate in selected children over 6 months with mild symptoms. OME generally does not benefit from antibiotics, antihistamines, or decongestants, and is often managed with observation. CSOM requires topical antibiotics and often surgical intervention, especially if cholesteatoma is present.
Surgical options include tympanostomy tube placement for persistent effusion or recurrent infections, and adenoidectomy in selected cases. Pain control with analgesics is essential in all patients regardless of antibiotic use.
The prognosis for acute otitis media is excellent with appropriate treatment. However, complications can occur, particularly in untreated or severe cases, including mastoiditis, hearing loss, facial nerve paralysis, labyrinthitis, and intracranial infections such as meningitis or brain abscess. Careful follow-up is especially important in children with persistent effusion to prevent long-term hearing and developmental issues.
Otitis media refers to inflammation of the middle ear, involving the mucosa and periosteum, and encompasses several clinical forms including acute otitis media (AOM), recurrent AOM, otitis media with effusion (OME), and chronic suppurative otitis media (CSOM). Acute otitis media is defined by the presence of middle-ear fluid along with signs of acute infection, whereas OME involves persistent fluid without active infection, and CSOM is characterized by chronic ear discharge through a perforated tympanic membrane, sometimes associated with cholesteatoma.
This condition is extremely common in children, with more than two-thirds experiencing at least one episode before age 3, and a peak incidence between 6–24 months. It is far less common in adults. Risk factors include eustachian tube dysfunction (often following viral upper respiratory infections), daycare attendance, passive smoking, congenital anomalies (e.g., cleft palate), immunodeficiency, and early age of first infection. Preventive strategies emphasize vaccination (pneumococcal, Haemophilus influenzae, influenza), breastfeeding, and appropriate early treatment.
The pathophysiology centers on eustachian tube dysfunction, leading to fluid accumulation in the middle ear, which serves as a medium for microbial growth. Viral infections often precede bacterial infection by causing mucosal swelling and obstruction.
The etiology varies by age and clinical form. In children, the most common pathogens are Streptococcus pneumoniae, Haemophilus influenzae (mostly nontypable), and Moraxella catarrhalis. Other organisms include group A streptococci and Staphylococcus aureus. In neonates, group B streptococci and gram-negative bacilli are important, while in adults, H. influenzae and S. pneumoniae predominate. Chronic suppurative otitis media often involves Pseudomonas aeruginosa, S. aureus, enteric gram-negative bacilli, and anaerobes.
Clinically, acute otitis media presents with ear pain, fever, and hearing loss, while infants may show nonspecific symptoms such as irritability or feeding difficulties. OME is often asymptomatic but may cause a feeling of fullness or mild hearing loss, whereas CSOM presents with chronic purulent discharge and hearing impairment.
Diagnosis relies on otoscopic examination, which typically shows a bulging, erythematous, and immobile tympanic membrane in acute disease, while OME shows a dull, hypomobile membrane without bulging. Tympanometry and hearing tests can help confirm middle-ear fluid and assess hearing loss. In complicated or chronic cases, CT imaging may be required to evaluate for cholesteatoma or mastoid involvement.
Treatment depends on the clinical scenario. Amoxicillin remains the first-line therapy for most cases of acute otitis media, with alternatives such as amoxicillin-clavulanate or cephalosporins used in resistant or recurrent cases. Macrolides or TMP-SMX may be used in penicillin-allergic patients. A watchful waiting approach may be appropriate in selected children over 6 months with mild symptoms. OME generally does not benefit from antibiotics, antihistamines, or decongestants, and is often managed with observation. CSOM requires topical antibiotics and often surgical intervention, especially if cholesteatoma is present.
Surgical options include tympanostomy tube placement for persistent effusion or recurrent infections, and adenoidectomy in selected cases. Pain control with analgesics is essential in all patients regardless of antibiotic use.
The prognosis for acute otitis media is excellent with appropriate treatment. However, complications can occur, particularly in untreated or severe cases, including mastoiditis, hearing loss, facial nerve paralysis, labyrinthitis, and intracranial infections such as meningitis or brain abscess. Careful follow-up is especially important in children with persistent effusion to prevent long-term hearing and developmental issues.
- Published on
Infectious disease and microbiology – Otitis externa
Otitis externa is an infection of the external auditory canal and is classified into four main types: acute localized, acute diffuse (swimmer’s ear), chronic, and invasive (malignant or necrotizing) otitis externa, the latter being a severe form that extends beyond the ear canal into surrounding soft tissue and bone. While most forms are common—affecting approximately 4 per 1000 people annually—the invasive form is rare but potentially life-threatening.
Risk factors vary by type. Hot, humid climates, frequent water exposure, and mechanical trauma (e.g., scratching or use of cotton swabs) predispose to acute diffuse otitis externa. In contrast, elderly patients, diabetics, and immunocompromised individuals are at higher risk for the invasive form. Preventive strategies include avoiding trauma to the ear canal and maintaining good diabetic control.
Pathophysiologically, disruption of the ear canal’s natural defenses—such as reduced acidity or decreased antimicrobial components like lysozyme and immunoglobulins (IgA, IgG)—facilitates microbial growth. Pseudomonas aeruginosa plays a key role, particularly in invasive disease, through increased expression of virulence factors such as exotoxins.
The etiology depends on the subtype. Acute localized infections (furuncles) are typically caused by Staphylococcus aureus. Acute diffuse otitis externa is most commonly due to Pseudomonas aeruginosa, along with other gram-negative bacteria, S. aureus, and occasionally fungi like Aspergillus. Chronic otitis externa is often related to persistent irritation from middle ear infections. Invasive otitis externa is most frequently caused by P. aeruginosa (>95% of cases), though other bacteria and fungi may be involved.
Clinically, patients with acute disease present with ear pain (otalgia), itching (pruritus), and sometimes discharge, with pain often worsened by manipulation of the auricle. Chronic cases tend to cause itching rather than pain. Invasive otitis externa presents more severely, with intense pain, purulent drainage, granulation tissue in the ear canal, and possible cranial nerve involvement (especially facial nerve palsy).
Diagnosis is primarily clinical and relies heavily on otoscopic examination. In invasive disease, laboratory findings may show a normal white blood cell count but elevated erythrocyte sedimentation rate. Imaging with CT (for bone involvement) and MRI (for soft tissue extension) is essential to assess disease extent. Deep tissue biopsy may be required to confirm diagnosis and exclude malignancy.
Treatment depends on severity. Topical antibiotic drops (often combined with corticosteroids) are the mainstay for uncomplicated cases, along with ear canal cleaning and moisture avoidance. Oral antibiotics are used if local therapy fails. Invasive otitis externa requires prolonged intravenous antipseudomonal antibiotics (6–8 weeks) such as ciprofloxacin, ceftazidime, cefepime, or carbapenems, along with meticulous canal care. Antifungal therapy is indicated when fungal pathogens are identified.
The prognosis is generally excellent for uncomplicated cases. In invasive otitis externa, outcomes have improved significantly, with up to 95% cure rates, although prognosis worsens with cranial nerve involvement, fungal infection, bilateral disease, or underlying immunosuppression.
Complications of invasive disease can be severe and include spread to the skull base, cranial nerve palsies, sigmoid sinus thrombosis, meningitis, and brain infection, making early recognition and aggressive treatment critical.
Otitis externa is an infection of the external auditory canal and is classified into four main types: acute localized, acute diffuse (swimmer’s ear), chronic, and invasive (malignant or necrotizing) otitis externa, the latter being a severe form that extends beyond the ear canal into surrounding soft tissue and bone. While most forms are common—affecting approximately 4 per 1000 people annually—the invasive form is rare but potentially life-threatening.
Risk factors vary by type. Hot, humid climates, frequent water exposure, and mechanical trauma (e.g., scratching or use of cotton swabs) predispose to acute diffuse otitis externa. In contrast, elderly patients, diabetics, and immunocompromised individuals are at higher risk for the invasive form. Preventive strategies include avoiding trauma to the ear canal and maintaining good diabetic control.
Pathophysiologically, disruption of the ear canal’s natural defenses—such as reduced acidity or decreased antimicrobial components like lysozyme and immunoglobulins (IgA, IgG)—facilitates microbial growth. Pseudomonas aeruginosa plays a key role, particularly in invasive disease, through increased expression of virulence factors such as exotoxins.
The etiology depends on the subtype. Acute localized infections (furuncles) are typically caused by Staphylococcus aureus. Acute diffuse otitis externa is most commonly due to Pseudomonas aeruginosa, along with other gram-negative bacteria, S. aureus, and occasionally fungi like Aspergillus. Chronic otitis externa is often related to persistent irritation from middle ear infections. Invasive otitis externa is most frequently caused by P. aeruginosa (>95% of cases), though other bacteria and fungi may be involved.
Clinically, patients with acute disease present with ear pain (otalgia), itching (pruritus), and sometimes discharge, with pain often worsened by manipulation of the auricle. Chronic cases tend to cause itching rather than pain. Invasive otitis externa presents more severely, with intense pain, purulent drainage, granulation tissue in the ear canal, and possible cranial nerve involvement (especially facial nerve palsy).
Diagnosis is primarily clinical and relies heavily on otoscopic examination. In invasive disease, laboratory findings may show a normal white blood cell count but elevated erythrocyte sedimentation rate. Imaging with CT (for bone involvement) and MRI (for soft tissue extension) is essential to assess disease extent. Deep tissue biopsy may be required to confirm diagnosis and exclude malignancy.
Treatment depends on severity. Topical antibiotic drops (often combined with corticosteroids) are the mainstay for uncomplicated cases, along with ear canal cleaning and moisture avoidance. Oral antibiotics are used if local therapy fails. Invasive otitis externa requires prolonged intravenous antipseudomonal antibiotics (6–8 weeks) such as ciprofloxacin, ceftazidime, cefepime, or carbapenems, along with meticulous canal care. Antifungal therapy is indicated when fungal pathogens are identified.
The prognosis is generally excellent for uncomplicated cases. In invasive otitis externa, outcomes have improved significantly, with up to 95% cure rates, although prognosis worsens with cranial nerve involvement, fungal infection, bilateral disease, or underlying immunosuppression.
Complications of invasive disease can be severe and include spread to the skull base, cranial nerve palsies, sigmoid sinus thrombosis, meningitis, and brain infection, making early recognition and aggressive treatment critical.
- Published on
Infectious disease and microbiology – Osteomyelitis
Osteomyelitis is an infection of bone, most commonly caused by bacteria and only rarely by fungi. It may present as acute disease, developing over days to weeks, or as chronic osteomyelitis, which evolves over months or years and is often associated with necrotic bone (sequestrum). The condition has an estimated incidence of 10–100 cases per 100,000 population and arises in a variety of clinical settings depending on host factors and route of infection.
Several risk factors predispose individuals to osteomyelitis, including diabetes mellitus (especially with foot ulcers), intravenous drug use, peripheral vascular disease, trauma, immunosuppression, and prior surgery or prosthetic implants. Certain organisms are associated with specific populations—for example, Salmonella in patients with sickle cell disease and Pseudomonas aeruginosa in intravenous drug users or puncture wounds through footwear. Preventive strategies emphasize good diabetic foot care and maintaining sterile surgical conditions, particularly for prosthetic procedures.
Infection reaches bone through three principal mechanisms: hematogenous spread, direct inoculation (trauma or surgery), or contiguous spread from nearby infected tissues. Once established, infection can involve the cortex, medullary cavity, and periosteum, leading to inflammation, abscess formation, and eventual bone necrosis. In children, infection commonly affects the metaphysis of long bones, whereas in adults, vertebral involvement is more typical.
The etiology is broad, with Staphylococcus aureus being the most common pathogen overall. Other causes include gram-negative organisms (e.g., Enterobacteriaceae), Pseudomonas, coagulase-negative staphylococci (especially in prosthetic infections), Mycobacterium tuberculosis, fungi such as Candida or endemic mycoses, and less commonly Brucella or organisms related to travel exposures.
Clinically, patients often present with localized bone pain, fever, swelling, and warmth over the affected area. Chronic cases may feature sinus tract formation with drainage. Recurrent or persistent cellulitis over a bony area should raise suspicion for underlying osteomyelitis. Diagnosis relies on a combination of laboratory testing and imaging, but the gold standard is bone biopsy for culture and histopathology, ideally obtained before antibiotic therapy. Blood cultures may identify the organism in up to 40% of acute cases, while inflammatory markers such as ESR are useful for monitoring disease activity.
Imaging plays a crucial role: plain X-rays may initially be normal, while MRI is highly sensitive, especially for spinal disease. CT scans can detect early cortical changes, and radionuclide scans are useful for early detection and identifying multifocal involvement. Advanced imaging such as PET may be helpful in chronic or unclear cases.
Management requires a combined medical and surgical approach. Prolonged antibiotic therapy (typically ≥6 weeks) is essential and should be tailored to the identified organism. For example, methicillin-susceptible S. aureus is treated with nafcillin or oxacillin, while MRSA requires vancomycin or alternative agents. Gram-negative infections are treated with fluoroquinolones or third-generation cephalosporins, and Pseudomonas infections require antipseudomonal agents. Importantly, surgical debridement of necrotic bone is often necessary, especially in chronic disease, and removal of infected prosthetic material may be required.
The prognosis is generally good for acute osteomyelitis with timely treatment but more guarded in chronic cases, where recurrence is common. Complications can be severe and include bone destruction, pathological fractures, epidural abscess with spinal cord compression, cranial neuropathies (in skull base involvement), amyloidosis, and even malignant transformation (Marjolin’s ulcer). Long-term follow-up is essential, as clinical and radiologic resolution may lag behind actual disease control.
Osteomyelitis is an infection of bone, most commonly caused by bacteria and only rarely by fungi. It may present as acute disease, developing over days to weeks, or as chronic osteomyelitis, which evolves over months or years and is often associated with necrotic bone (sequestrum). The condition has an estimated incidence of 10–100 cases per 100,000 population and arises in a variety of clinical settings depending on host factors and route of infection.
Several risk factors predispose individuals to osteomyelitis, including diabetes mellitus (especially with foot ulcers), intravenous drug use, peripheral vascular disease, trauma, immunosuppression, and prior surgery or prosthetic implants. Certain organisms are associated with specific populations—for example, Salmonella in patients with sickle cell disease and Pseudomonas aeruginosa in intravenous drug users or puncture wounds through footwear. Preventive strategies emphasize good diabetic foot care and maintaining sterile surgical conditions, particularly for prosthetic procedures.
Infection reaches bone through three principal mechanisms: hematogenous spread, direct inoculation (trauma or surgery), or contiguous spread from nearby infected tissues. Once established, infection can involve the cortex, medullary cavity, and periosteum, leading to inflammation, abscess formation, and eventual bone necrosis. In children, infection commonly affects the metaphysis of long bones, whereas in adults, vertebral involvement is more typical.
The etiology is broad, with Staphylococcus aureus being the most common pathogen overall. Other causes include gram-negative organisms (e.g., Enterobacteriaceae), Pseudomonas, coagulase-negative staphylococci (especially in prosthetic infections), Mycobacterium tuberculosis, fungi such as Candida or endemic mycoses, and less commonly Brucella or organisms related to travel exposures.
Clinically, patients often present with localized bone pain, fever, swelling, and warmth over the affected area. Chronic cases may feature sinus tract formation with drainage. Recurrent or persistent cellulitis over a bony area should raise suspicion for underlying osteomyelitis. Diagnosis relies on a combination of laboratory testing and imaging, but the gold standard is bone biopsy for culture and histopathology, ideally obtained before antibiotic therapy. Blood cultures may identify the organism in up to 40% of acute cases, while inflammatory markers such as ESR are useful for monitoring disease activity.
Imaging plays a crucial role: plain X-rays may initially be normal, while MRI is highly sensitive, especially for spinal disease. CT scans can detect early cortical changes, and radionuclide scans are useful for early detection and identifying multifocal involvement. Advanced imaging such as PET may be helpful in chronic or unclear cases.
Management requires a combined medical and surgical approach. Prolonged antibiotic therapy (typically ≥6 weeks) is essential and should be tailored to the identified organism. For example, methicillin-susceptible S. aureus is treated with nafcillin or oxacillin, while MRSA requires vancomycin or alternative agents. Gram-negative infections are treated with fluoroquinolones or third-generation cephalosporins, and Pseudomonas infections require antipseudomonal agents. Importantly, surgical debridement of necrotic bone is often necessary, especially in chronic disease, and removal of infected prosthetic material may be required.
The prognosis is generally good for acute osteomyelitis with timely treatment but more guarded in chronic cases, where recurrence is common. Complications can be severe and include bone destruction, pathological fractures, epidural abscess with spinal cord compression, cranial neuropathies (in skull base involvement), amyloidosis, and even malignant transformation (Marjolin’s ulcer). Long-term follow-up is essential, as clinical and radiologic resolution may lag behind actual disease control.
- Published on
Infectious disease and microbiology – Nocardiosis
Nocardiosis is an invasive opportunistic infection caused by Nocardia species, a group of aerobic, Gram-positive, branching filamentous bacteria belonging to the order Actinomycetales. First described in 1889, the disease may present as localized or disseminated infection, most commonly involving the lungs, but it can spread hematogenously—especially to the central nervous system (CNS)—and virtually any organ, including the skin, heart, kidneys, bones, and soft tissues.
Clinical manifestations range from pulmonary disease (acute, chronic, or subclinical) to brain abscesses, cellulitis, lymphocutaneous disease, actinomycetoma, and keratitis.
The infection is typically acquired through inhalation of organisms from soil or organic matter, making the lungs the primary site of infection, although traumatic skin inoculation or mucosal entry can also occur. There is no significant person-to-person transmission. Approximately 1,000 cases occur annually in the United States, with most involving pulmonary or systemic disease. Although nocardiosis can affect individuals of any age, it is more common in adults and males, and while many patients are immunocompromised, up to one-third are immunocompetent.
Major risk factors include conditions that impair cell-mediated immunity, such as HIV/AIDS, malignancy, organ transplantation, corticosteroid or TNF-alpha inhibitor therapy, Cushing’s syndrome, and chronic granulomatous disease. The most common pathogen is Nocardia asteroides, though other species like N. brasiliensis are associated with cutaneous disease, particularly in tropical regions.
Clinically, nocardiosis presents with nonspecific symptoms, especially in pulmonary disease, including productive cough, fever, weight loss, malaise, and occasionally dyspnea or hemoptysis. The disease may follow a chronic or relapsing course, and dissemination—particularly to the brain—may initially be asymptomatic. Cutaneous forms present as cellulitis, nodules, ulcers, or lymphocutaneous spread, while actinomycetoma causes chronic, deforming lesions with draining sinuses. CNS involvement typically manifests as brain abscesses, which are often multiple and indolent.
Diagnosis relies on microscopic and microbiological identification. Specimens such as sputum or pus reveal branching, beaded Gram-positive filaments, often requiring modified acid-fast staining. Cultures grow slowly and may take up to several weeks, forming chalky, pigmented colonies with a characteristic odor. Imaging studies such as chest X-ray or CT may show nodules, cavitations, or infiltrates, while brain imaging (CT/MRI) is essential when CNS involvement is suspected.
Treatment is prolonged and often requires combination antimicrobial therapy. First-line treatment includes trimethoprim-sulfamethoxazole (TMP-SMX), with alternatives such as amikacin, imipenem, ceftriaxone, or minocycline, depending on disease severity and susceptibility patterns. Therapy duration is typically 6–12 months, longer for CNS or immunocompromised cases. Surgical drainage or excision may be necessary for large abscesses or extensive disease.
Close follow-up is essential due to the risk of relapse or dissemination, even after apparent clinical improvement. Prognosis depends on immune status and extent of disease; mortality is relatively low in immunocompetent patients with localized pulmonary disease (~15%) but significantly higher in disseminated or CNS infections. Complications include brain abscess rupture, spinal cord compression, empyema, fistula formation, and widespread organ involvement, highlighting the need for early diagnosis and aggressive management.
Nocardiosis is an invasive opportunistic infection caused by Nocardia species, a group of aerobic, Gram-positive, branching filamentous bacteria belonging to the order Actinomycetales. First described in 1889, the disease may present as localized or disseminated infection, most commonly involving the lungs, but it can spread hematogenously—especially to the central nervous system (CNS)—and virtually any organ, including the skin, heart, kidneys, bones, and soft tissues.
Clinical manifestations range from pulmonary disease (acute, chronic, or subclinical) to brain abscesses, cellulitis, lymphocutaneous disease, actinomycetoma, and keratitis.
The infection is typically acquired through inhalation of organisms from soil or organic matter, making the lungs the primary site of infection, although traumatic skin inoculation or mucosal entry can also occur. There is no significant person-to-person transmission. Approximately 1,000 cases occur annually in the United States, with most involving pulmonary or systemic disease. Although nocardiosis can affect individuals of any age, it is more common in adults and males, and while many patients are immunocompromised, up to one-third are immunocompetent.
Major risk factors include conditions that impair cell-mediated immunity, such as HIV/AIDS, malignancy, organ transplantation, corticosteroid or TNF-alpha inhibitor therapy, Cushing’s syndrome, and chronic granulomatous disease. The most common pathogen is Nocardia asteroides, though other species like N. brasiliensis are associated with cutaneous disease, particularly in tropical regions.
Clinically, nocardiosis presents with nonspecific symptoms, especially in pulmonary disease, including productive cough, fever, weight loss, malaise, and occasionally dyspnea or hemoptysis. The disease may follow a chronic or relapsing course, and dissemination—particularly to the brain—may initially be asymptomatic. Cutaneous forms present as cellulitis, nodules, ulcers, or lymphocutaneous spread, while actinomycetoma causes chronic, deforming lesions with draining sinuses. CNS involvement typically manifests as brain abscesses, which are often multiple and indolent.
Diagnosis relies on microscopic and microbiological identification. Specimens such as sputum or pus reveal branching, beaded Gram-positive filaments, often requiring modified acid-fast staining. Cultures grow slowly and may take up to several weeks, forming chalky, pigmented colonies with a characteristic odor. Imaging studies such as chest X-ray or CT may show nodules, cavitations, or infiltrates, while brain imaging (CT/MRI) is essential when CNS involvement is suspected.
Treatment is prolonged and often requires combination antimicrobial therapy. First-line treatment includes trimethoprim-sulfamethoxazole (TMP-SMX), with alternatives such as amikacin, imipenem, ceftriaxone, or minocycline, depending on disease severity and susceptibility patterns. Therapy duration is typically 6–12 months, longer for CNS or immunocompromised cases. Surgical drainage or excision may be necessary for large abscesses or extensive disease.
Close follow-up is essential due to the risk of relapse or dissemination, even after apparent clinical improvement. Prognosis depends on immune status and extent of disease; mortality is relatively low in immunocompetent patients with localized pulmonary disease (~15%) but significantly higher in disseminated or CNS infections. Complications include brain abscess rupture, spinal cord compression, empyema, fistula formation, and widespread organ involvement, highlighting the need for early diagnosis and aggressive management.
- Published on
Infectious disease and microbiology – Neuropathies, infectious
Infectious neuropathies refer to inflammation or dysfunction of peripheral nerves caused by infectious agents or their toxins, including viruses, bacteria, parasites, and toxin-mediated mechanisms. A key example is Guillain-Barré syndrome (GBS), an immune-mediated neuropathy often triggered by a preceding infection. GBS has an incidence of approximately 1.2–3 cases per 100,000 people and can occur at any age, with peaks in young adults and older individuals. Risk factors vary depending on the cause and include immunosuppression (e.g., HIV/AIDS), advanced age, and exposure to endemic infections such as Lyme disease, leprosy, or Chagas disease. Preventive measures include vaccination (e.g., zoster, rabies, tetanus) and, in specific situations like tick exposure, prophylactic antibiotics.
The pathophysiology differs by condition but often involves either direct infection of nerve tissue or immune-mediated damage. In GBS, a prior infection triggers an immune response that cross-reacts with peripheral nerve components, leading to demyelination (most common) or axonal injury. Infectious causes include viruses such as herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and HIV; bacteria such as Borrelia burgdorferi (Lyme disease) and Mycobacterium leprae (leprosy); parasites like Trypanosoma cruzi; and toxins from organisms such as Clostridium botulinum and Corynebacterium diphtheriae. Additionally, many cases of GBS are preceded by infections like Campylobacter jejuni, respiratory viruses, or gastrointestinal illnesses.
Clinical presentation depends on the underlying cause. Viral neuropathies often present with pain and dermatomal rashes, as seen in herpes zoster, or progressive sensory and motor deficits, as in CMV or HIV-related neuropathies. Bacterial causes such as Lyme disease may produce cranial nerve palsies, meningitis, or radiculopathy, while leprosy leads to sensory loss and nerve thickening. Toxin-mediated neuropathies have distinctive features, such as descending paralysis in botulism or muscle spasms in tetanus. In contrast, GBS typically begins with ascending symmetric weakness starting in the lower limbs, progressing over days to weeks and potentially involving respiratory muscles and autonomic dysfunction.
Diagnosis relies on clinical evaluation supported by laboratory and imaging studies. Tests may include detection of viral DNA (e.g., CMV in cerebrospinal fluid), serologic testing for Lyme disease, toxin identification in suspected botulism, and cerebrospinal fluid analysis in GBS, which classically shows elevated protein with normal cell count. Imaging such as MRI may demonstrate nerve root enhancement, while nerve conduction studies help assess the extent of nerve involvement.
Management is directed at the underlying cause. Antiviral therapy (e.g., acyclovir for HSV/VZV, ganciclovir for CMV) is used for viral infections, while bacterial causes like Lyme disease are treated with doxycycline or ceftriaxone. Toxin-mediated conditions require antitoxins and supportive care. For GBS, early treatment with plasmapheresis or intravenous immunoglobulin (IVIG) is essential to reduce disease severity and duration. Supportive care, including monitoring for respiratory failure, managing autonomic instability, and rehabilitation, plays a critical role in recovery.
Complications can be significant, particularly in GBS, where patients may experience residual neurologic deficits, recurrence, or prolonged disability. Early recognition and prompt management are crucial to improving outcomes and reducing long-term morbidity.
Infectious neuropathies refer to inflammation or dysfunction of peripheral nerves caused by infectious agents or their toxins, including viruses, bacteria, parasites, and toxin-mediated mechanisms. A key example is Guillain-Barré syndrome (GBS), an immune-mediated neuropathy often triggered by a preceding infection. GBS has an incidence of approximately 1.2–3 cases per 100,000 people and can occur at any age, with peaks in young adults and older individuals. Risk factors vary depending on the cause and include immunosuppression (e.g., HIV/AIDS), advanced age, and exposure to endemic infections such as Lyme disease, leprosy, or Chagas disease. Preventive measures include vaccination (e.g., zoster, rabies, tetanus) and, in specific situations like tick exposure, prophylactic antibiotics.
The pathophysiology differs by condition but often involves either direct infection of nerve tissue or immune-mediated damage. In GBS, a prior infection triggers an immune response that cross-reacts with peripheral nerve components, leading to demyelination (most common) or axonal injury. Infectious causes include viruses such as herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and HIV; bacteria such as Borrelia burgdorferi (Lyme disease) and Mycobacterium leprae (leprosy); parasites like Trypanosoma cruzi; and toxins from organisms such as Clostridium botulinum and Corynebacterium diphtheriae. Additionally, many cases of GBS are preceded by infections like Campylobacter jejuni, respiratory viruses, or gastrointestinal illnesses.
Clinical presentation depends on the underlying cause. Viral neuropathies often present with pain and dermatomal rashes, as seen in herpes zoster, or progressive sensory and motor deficits, as in CMV or HIV-related neuropathies. Bacterial causes such as Lyme disease may produce cranial nerve palsies, meningitis, or radiculopathy, while leprosy leads to sensory loss and nerve thickening. Toxin-mediated neuropathies have distinctive features, such as descending paralysis in botulism or muscle spasms in tetanus. In contrast, GBS typically begins with ascending symmetric weakness starting in the lower limbs, progressing over days to weeks and potentially involving respiratory muscles and autonomic dysfunction.
Diagnosis relies on clinical evaluation supported by laboratory and imaging studies. Tests may include detection of viral DNA (e.g., CMV in cerebrospinal fluid), serologic testing for Lyme disease, toxin identification in suspected botulism, and cerebrospinal fluid analysis in GBS, which classically shows elevated protein with normal cell count. Imaging such as MRI may demonstrate nerve root enhancement, while nerve conduction studies help assess the extent of nerve involvement.
Management is directed at the underlying cause. Antiviral therapy (e.g., acyclovir for HSV/VZV, ganciclovir for CMV) is used for viral infections, while bacterial causes like Lyme disease are treated with doxycycline or ceftriaxone. Toxin-mediated conditions require antitoxins and supportive care. For GBS, early treatment with plasmapheresis or intravenous immunoglobulin (IVIG) is essential to reduce disease severity and duration. Supportive care, including monitoring for respiratory failure, managing autonomic instability, and rehabilitation, plays a critical role in recovery.
Complications can be significant, particularly in GBS, where patients may experience residual neurologic deficits, recurrence, or prolonged disability. Early recognition and prompt management are crucial to improving outcomes and reducing long-term morbidity.
- Published on
Infectious disease and microbiology – Necrotizing soft-tissue infections
Necrotizing soft-tissue infections (NSTIs) are rapidly progressive, life-threatening infections that involve the fascia and may extend to muscles, leading to extensive tissue destruction. They usually arise after a break in the skin, such as trauma, surgery, or even minor events like insect bites, although in many cases no clear initiating factor is identified. Clinically, they may present as necrotizing cellulitis, necrotizing fasciitis, or pyomyositis, and they are associated with high mortality rates exceeding 20%, often reaching around one-third of cases.
The incidence of NSTIs has been increasing, and although still uncommon, most clinicians will encounter at least one case during their practice. Risk factors include immunocompromised states, particularly diabetes mellitus and peripheral vascular disease, as well as obesity, chronic liver or renal disease, HIV infection, intravenous drug use, older age, and frequent hospitalizations. Certain populations, such as athletes or institutionalized individuals, are more prone to infections caused by community-associated MRSA.
Pathophysiologically, bacteria invade subcutaneous tissues and spread rapidly along fascial planes. The production of toxins and enzymes leads to local ischemia, impaired immune response, and widespread necrosis, allowing the infection to advance quickly. Most cases are polymicrobial (Type 1), involving a mixture of aerobic and anaerobic organisms, while others are monomicrobial (Types 2 and 3), commonly caused by Group A Streptococcus, Staphylococcus aureus, or Clostridium species.
Clinically, early symptoms may appear deceptively mild, with pain, erythema, swelling, and tachycardia, but the hallmark is pain out of proportion to physical findings. As the disease progresses, patients develop skin discoloration, bullae, crepitus, anesthesia, and systemic signs such as fever, hypotension, and shock, often rapidly progressing to sepsis and multi-organ failure. Diagnosis is primarily clinical, and urgent surgical exploration remains the gold standard, as delays can be fatal. Laboratory findings and scoring systems such as the LRINEC score may support suspicion, while imaging (CT or MRI) can reveal fascial thickening or gas in tissues but should not delay treatment.
Management requires immediate and aggressive intervention, combining broad-spectrum intravenous antibiotics with early surgical debridement, which is the most critical factor in reducing mortality. Empiric antibiotic therapy should cover gram-positive, gram-negative, and anaerobic organisms, with adjustments based on culture results. Repeated surgical exploration is often necessary, and in severe cases, amputation may be required. Patients typically require intensive care support, including fluid resuscitation, hemodynamic stabilization, and nutritional support.
Despite advances in management, prognosis remains serious. Mortality has improved with early recognition and aggressive treatment but remains high, and survivors often face significant morbidity. Complications include sepsis, acute respiratory distress syndrome, renal failure, nosocomial infections, and limb loss, highlighting the importance of prompt diagnosis and multidisciplinary management.
Necrotizing soft-tissue infections (NSTIs) are rapidly progressive, life-threatening infections that involve the fascia and may extend to muscles, leading to extensive tissue destruction. They usually arise after a break in the skin, such as trauma, surgery, or even minor events like insect bites, although in many cases no clear initiating factor is identified. Clinically, they may present as necrotizing cellulitis, necrotizing fasciitis, or pyomyositis, and they are associated with high mortality rates exceeding 20%, often reaching around one-third of cases.
The incidence of NSTIs has been increasing, and although still uncommon, most clinicians will encounter at least one case during their practice. Risk factors include immunocompromised states, particularly diabetes mellitus and peripheral vascular disease, as well as obesity, chronic liver or renal disease, HIV infection, intravenous drug use, older age, and frequent hospitalizations. Certain populations, such as athletes or institutionalized individuals, are more prone to infections caused by community-associated MRSA.
Pathophysiologically, bacteria invade subcutaneous tissues and spread rapidly along fascial planes. The production of toxins and enzymes leads to local ischemia, impaired immune response, and widespread necrosis, allowing the infection to advance quickly. Most cases are polymicrobial (Type 1), involving a mixture of aerobic and anaerobic organisms, while others are monomicrobial (Types 2 and 3), commonly caused by Group A Streptococcus, Staphylococcus aureus, or Clostridium species.
Clinically, early symptoms may appear deceptively mild, with pain, erythema, swelling, and tachycardia, but the hallmark is pain out of proportion to physical findings. As the disease progresses, patients develop skin discoloration, bullae, crepitus, anesthesia, and systemic signs such as fever, hypotension, and shock, often rapidly progressing to sepsis and multi-organ failure. Diagnosis is primarily clinical, and urgent surgical exploration remains the gold standard, as delays can be fatal. Laboratory findings and scoring systems such as the LRINEC score may support suspicion, while imaging (CT or MRI) can reveal fascial thickening or gas in tissues but should not delay treatment.
Management requires immediate and aggressive intervention, combining broad-spectrum intravenous antibiotics with early surgical debridement, which is the most critical factor in reducing mortality. Empiric antibiotic therapy should cover gram-positive, gram-negative, and anaerobic organisms, with adjustments based on culture results. Repeated surgical exploration is often necessary, and in severe cases, amputation may be required. Patients typically require intensive care support, including fluid resuscitation, hemodynamic stabilization, and nutritional support.
Despite advances in management, prognosis remains serious. Mortality has improved with early recognition and aggressive treatment but remains high, and survivors often face significant morbidity. Complications include sepsis, acute respiratory distress syndrome, renal failure, nosocomial infections, and limb loss, highlighting the importance of prompt diagnosis and multidisciplinary management.
- Published on
Infectious disease and microbiology – Myositis
Myositis is an inflammatory condition of skeletal muscles that may arise from infectious causes—including bacteria, viruses, fungi, parasites, and mycobacteria—or from noninfectious conditions. A specific form, pyomyositis, refers to a hematogenous bacterial infection of muscle that frequently leads to abscess formation, whereas acute bacterial myositis involves diffuse muscle infection without abscess. The epidemiology varies depending on the causative organism, but pyomyositis is relatively rare in temperate regions and more common in tropical areas, where it may account for a notable proportion of hospital admissions. Risk factors include immunocompromised states such as HIV infection, chronic illnesses like diabetes and malignancy, alcoholism, trauma, surgery, obesity, and residence in tropical climates.
The pathophysiology often involves muscle injury or trauma, which may create a susceptible environment for infection due to local infarction or hemorrhage. A wide range of pathogens can cause myositis: viral agents such as influenza, HIV, and herpes viruses; parasitic organisms like Trichinella spiralis, Toxoplasma gondii, and Echinococcus; and bacterial pathogens, most notably Staphylococcus aureus, which accounts for the majority of pyomyositis cases. Other bacterial causes include streptococci, clostridia (leading to gas gangrene), and mixed aerobic and anaerobic organisms. Fungal infections and infections related to aquatic exposure (e.g., Aeromonas hydrophila, Vibrio vulnificus) are less common but clinically important.
Clinically, myositis often presents insidiously with localized muscle pain and fever, progressing to swelling, induration, and marked tenderness. Deep muscle infections may lack overlying skin changes, making diagnosis challenging. In advanced cases, findings such as crepitus, malodorous discharge, hemorrhagic bullae, or systemic signs of sepsis may appear. Laboratory evaluation typically shows leukocytosis and elevated muscle enzymes, while cultures from deep tissue or aspirated material are essential for identifying the causative organism. Imaging studies such as CT or MRI help determine the extent of muscle involvement and detect abscess formation, while ultrasound can assist in emergency settings.
Management usually requires a combined medical and surgical approach, particularly for bacterial myositis. Abscesses should be drained, and empiric antibiotic therapy should cover common pathogens such as S. aureus, with adjustments based on culture results. Severe infections, such as those caused by streptococci or clostridia, require urgent surgical debridement and high-dose antibiotics, often including penicillin and clindamycin. Treatment of parasitic infections depends on the specific organism, while viral myositis is generally managed supportively. Additional therapies, such as hyperbaric oxygen for clostridial infections or immunoglobulin in toxic shock, may be indicated in selected cases.
Patients often require hospitalization, especially in bacterial or severe parasitic cases, with close monitoring and supportive care. Despite treatment, prognosis can be serious in severe infections, particularly those caused by streptococci or clostridia, which carry high mortality rates. Potential complications include bacteremia, septic shock, limb necrosis, toxic shock syndrome, and death, underscoring the importance of early recognition and aggressive management.
Myositis is an inflammatory condition of skeletal muscles that may arise from infectious causes—including bacteria, viruses, fungi, parasites, and mycobacteria—or from noninfectious conditions. A specific form, pyomyositis, refers to a hematogenous bacterial infection of muscle that frequently leads to abscess formation, whereas acute bacterial myositis involves diffuse muscle infection without abscess. The epidemiology varies depending on the causative organism, but pyomyositis is relatively rare in temperate regions and more common in tropical areas, where it may account for a notable proportion of hospital admissions. Risk factors include immunocompromised states such as HIV infection, chronic illnesses like diabetes and malignancy, alcoholism, trauma, surgery, obesity, and residence in tropical climates.
The pathophysiology often involves muscle injury or trauma, which may create a susceptible environment for infection due to local infarction or hemorrhage. A wide range of pathogens can cause myositis: viral agents such as influenza, HIV, and herpes viruses; parasitic organisms like Trichinella spiralis, Toxoplasma gondii, and Echinococcus; and bacterial pathogens, most notably Staphylococcus aureus, which accounts for the majority of pyomyositis cases. Other bacterial causes include streptococci, clostridia (leading to gas gangrene), and mixed aerobic and anaerobic organisms. Fungal infections and infections related to aquatic exposure (e.g., Aeromonas hydrophila, Vibrio vulnificus) are less common but clinically important.
Clinically, myositis often presents insidiously with localized muscle pain and fever, progressing to swelling, induration, and marked tenderness. Deep muscle infections may lack overlying skin changes, making diagnosis challenging. In advanced cases, findings such as crepitus, malodorous discharge, hemorrhagic bullae, or systemic signs of sepsis may appear. Laboratory evaluation typically shows leukocytosis and elevated muscle enzymes, while cultures from deep tissue or aspirated material are essential for identifying the causative organism. Imaging studies such as CT or MRI help determine the extent of muscle involvement and detect abscess formation, while ultrasound can assist in emergency settings.
Management usually requires a combined medical and surgical approach, particularly for bacterial myositis. Abscesses should be drained, and empiric antibiotic therapy should cover common pathogens such as S. aureus, with adjustments based on culture results. Severe infections, such as those caused by streptococci or clostridia, require urgent surgical debridement and high-dose antibiotics, often including penicillin and clindamycin. Treatment of parasitic infections depends on the specific organism, while viral myositis is generally managed supportively. Additional therapies, such as hyperbaric oxygen for clostridial infections or immunoglobulin in toxic shock, may be indicated in selected cases.
Patients often require hospitalization, especially in bacterial or severe parasitic cases, with close monitoring and supportive care. Despite treatment, prognosis can be serious in severe infections, particularly those caused by streptococci or clostridia, which carry high mortality rates. Potential complications include bacteremia, septic shock, limb necrosis, toxic shock syndrome, and death, underscoring the importance of early recognition and aggressive management.
